Zusammenfassung
Toxoplasma gondii ist ein weltweit auftretender parasitärer Einzeller der Apicomplexa und somit ein naher Verwandter des Malariaerregers Plasmodium. Da T. gondii zum einen jede warmblütige Wirbeltierart als Zwischenwirt befällt und zum anderen eine weltweit sehr hohe Prävalenz aufweist, gehört die Toxoplasmose zu den international wichtigsten Lebensmittelerkrankungen. Mögliche Impfstoffe (humane wie veterinäre) spielen bei der Kontrolle dieser Erkrankung eine entscheidende Rolle.
Abstract
Toxoplasma gondii is a unicellular organism of the Apicomplexa that occurs worldwide and is therefore a close relative of the malaria pathogen Plasmodium. As T. gondii infests every warm-blooded vertebrate species as an intermediate host and has a very high prevalence worldwide, toxoplasmosis is one of the most important international foodborne diseases. Potential vaccines (human as well as veterinary) play a crucial role in controlling this disease.
Literatur
Adeyemi OS, Murata Y, Sugi T, Kato K (2017) Inorganic nanoparticles kill Toxoplasma gondii via changes in redox status and mitochondrial membrane potential. Int J Nanomed 12:1647–1661
Ammar S, Purple K, Gerhold R (2020) Toxoplasma gondii prevalence in hunter-killed mourning doves (Zenaida macroura) and rock pigeons (Columba livia) from East Tennessee, USA. J Wildl Dis 56(2):479–481
anses (2016) Toxoplasmose. https://www.anses.fr/fr/content/toxoplasmose. Zugegriffen: 13. Juni 2021
Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9(4):308–324
Attias M, Teixeira DE, Benchimol M, Vommaro RC, Crepaldi PH, De Souza W (2020) The life-cycle of Toxoplasma gondii reviewed using animations. Parasites Vectors 13:588
Bai MJ, Wang JL, Elsheikha HM, Liang QL, Chen K, Nie LB, Zhu XQ (2018) Functional characterization of dense granule proteins in Toxoplasma gondii RH strain using CRISPR-Cas9 system. Front Cell Infect Microbiol 8:300
Basavaraju A (2016) Toxoplasmosis in HIV infection: An overview. Trop Parasitol 6(2):129–135
Borkens Y (2020) Ist eine Malaria-Impfung möglich? – Verschiedene Impfkandidaten und ihr Potenzial gegen Plasmodium-Parasiten. Med Monatsschr Pharm 43(8):317–321
CDC’s Division of Parasitic Diseases and Malaria, DPDx (2020) Parasites—Toxoplasmosis (Toxoplasma infection): Biology. https://www.cdc.gov/parasites/toxoplasmosis/biology.html. Zugegriffen: 19. Mai 2021
CDC’s Division of Parasitic Diseases and Malaria, DPDx (2018) Parasites—toxoplasmosis (Toxoplasma infection): epidemiology & risk factors. https://www.cdc.gov/parasites/toxoplasmosis/epi.html#:~:text=Toxoplasmosis%20is%20caused%20by%20the,have%20been%20infected%20with%20Toxoplasma. Zugegriffen: 25. Mai 2021
Ching XT, Fong MY, Lau YL (2017) Evaluation of the protective effect of deoxyribonucleic acid vaccines encoding granule antigen 2 and 5 against acute toxoplasmosis in BALB/c mice. Am J Trop Med Hyg 96:1441–1447
Chu KB, Quan FS (2021) Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development. Vaccines 9:413
Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, Foulon W, Semprini AE, Dunn DT (2000) Sources of Toxoplasma infection in pregnant women: European multi centre case-control study. European Research Network on congenital Toxoplasmosis. BMJ 15:142–147
Deutschlandfunk (2008) Medizin: Ein Malaria-Medikament hilft gegen Toxoplasmose. https://www.deutschlandfunk.de/meldungen-liste-forschung-aktuell.1508.de.html?drn:news_id=83868. Zugegriffen: 23. Apr. 2021
Dimier-Poisson L, Carpentier R, N’Guyen TT, Dahmani F, Ducournau C, Berbeder D (2015) Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials 50:164–175
Dubey JP (1984) Experimental toxoplasmosis in sheep fed Toxoplasma gondii oocysts. Int Goat Sheep Res 2:93–104
Dubey JP, Urban JF Jr., Davis SW (1991) Protective immunity to toxoplasmosis in pigs vaccinated with a nonpersistent strain of Toxoplasma gondii. Am J Vet Res 52:1
Dubey JP (1998) Advances in the life cycle of Toxoplasma gondii. Int J Parasitol 28(7):1019–1024
El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Roberts CW, Lanar DE, Reed S, Fox C, Carter D, Alexander J, Sette A, Sidney J, Lorenzi H, Begeman IJ, Burkhard P, McLeod R (2017) Protein nanovaccine confers robust immunity against Toxoplasma. NPJ Vaccines 2:24
El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Reed S, Estes A, Estes A, Lykins J, Burkhard P, McLeod R (2020) Engineering and characterization of a novel self assembling protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. Sci Rep 10:16984
Flegr J (2013) How and why Toxoplasma makes us crazy. Trends Parasitol 29(4):156–163
Flegr J, Prandota J, Sovičkova M, Israili ZH (2014) Toxoplasmosis—A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. Plos One 9(3):e90203
Frenkel JK, Pfefferkorn ER, Smith DD, Fishback JL (1991) Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats. Am J Vet Res 52:759–763
Gibb DGA, Kakulas BA, Perret DH, Jenkyn DJ (1966) Toxoplasmosis in the rottnest quokka (Setonix brachyurus). Aust J Exp Biol Med Sci 44(6):665–672
Global Health, Division of Parasitic Diseases and Malaria (2018) Parasites—Toxoplasmosis (Toxoplasma infection): Treatment. https://www.cdc.gov/parasites/toxoplasmosis/treatment.html. Zugegriffen: 20. Aug. 2021
Götze S, Reinhardt A, Geissner A, Azzouz N, Tsai YH, Kurucz R, Varón SD, Seeberger PH (2015) Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a Toxoplasma gondii mouse challenge model. Glycobiology 25(9):984–991
Ishtiaq F, Swain S, Kumar SS (2021) Anopheles stephensi (Asian Malaria Mosquito). Trends Parasitol. https://doi.org/10.1016/j.pt.2021.03.009
Jenner E (1799) History of the inoculation of the Cow-Pox: Further observations on the Variolæ Vaccinæ, or Cow-Pox. Med Phys J 1(4):313–318
Jenner E (1800) Dr. Jenner, on the Vaccine Inoculation. Med Phys J 3(16):502–503
Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB (2001) Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 154(4):357–365
Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31:58–83
Lee DH, Kim AR, Lee SH, Quan FS (2016) Cross-protection induced by Toxoplasma gondii virus-like particle vaccine upon intraperitoneal route challenge. Acta Trop 164:77–83
Lee DH, Lee SH, Kim AR, Quan FS (2016) Virus-like nanoparticle vaccine confers protection against Toxoplasma gondii. PLoS ONE 11:e161231
Le Roux D, Djokic V, Morisse S, Chauvin C, Doré V, Lagrée AC, Voisin D, Villain Y, Grasset-Chevillot A, Boursin F, Su C, Perrot S, Vallée I, Seche E, Blaga R (2020) Toxoplasma gondii live attenuated strain in the feline host. Vaccine 38:1457–1466
Li Y, Zhou H (2018) Moving towards improved vaccines for Toxoplasma gondii. Expert Opin Biol Ther 18:273–280
Lung P, Yang J, Li Q (2020) Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale 12:5746–5763
Maldonado YA, Read JS, Committee on infectious diseases (2017) Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics 139(2):e20163860
Mandelbrot L, Kieffer F, Wallon M, Winer N, Massardier J, Picone O, Fuchs F, Benoist G, Garcia-Meric P, L’Ollivier C, Paris L, Piarroux R, Villena I, Peyron F (2021) Toxoplasmose pendant la grossesse: proposition actuelle de prise en charge pratique. Gynecol Obstet Fetil Senol. https://doi.org/10.1016/j.gofs.2021.03.003
Mateus-Pinilla NE, Hannon B, Weigel RM (2002) A computer simulation of the prevention of the transmission of Toxoplasma gondii on swine farms using a feline T. gondii vaccine. Prev Vet Med 55:17–36
McDermott DH, Heusinkveld LE, Zein WM, Sen HN, Marquessen MM, Parta M, Rosenzweig SD, Fahle GA, Keller MD, Wiley HE, Murphy PM (2019) Case Report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient [Version 2; peer review: 3 approved. F1000 Res 8:2. https://doi.org/10.12688/f1000research.16825.2
Mineo JR, Kasper LH (1994) Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG‑1 (P30). Exp Parasitol 79(1):11–20
Mohabati R, Babaie J, Amiri S, Talebzadeh M, Fard-Esfahani P, Darbouy M, Golkar M (2013) Expression and purification of recombinant ROP1 of Toxoplasma gondii in bacteria. Avicenna J Med Biotechnol 5(4):227–233
Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363(9425):1965–1976
Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R (2008) Novel Triazine JCP-2067‑B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis 2(3):e190
Nicolle C, Manceaux L (1908) Sur une infection a corps de Leishman (ou organismes voisons) du gondi. C R Acad Sci 147:736
Nicolle C, Manceaux L (1909) Sur un protozaire nouveau du gondi. C R Acad Sci 148:369
Opsteegh M, Spano F, Aubert D, Balea A, Burrells A, Cherchi S, Cornelissen JBWJ, Dam-Deisz C, Guitian J, Györke A, Innes EA, Katzer F, Limon G, Possenti A, Pozio E, Schares G, Villena I, Wisselink HJ, van der Giessen JWB (2019) The relationship between the presence of antibodies and direct detection of Toxoplasma gondii in slaughtered calves and cattle in four European countries. Int J Parasitol 49(7):515–522
Paululat A, Purschke G (2011) Toxoplasma. In: Paululat A, Purschke G (Hrsg) Wörterbuch der Zoologie, 8. Aufl. Spektrum Akademischer Verlag, Osnabrück, S 461
Pearson RD (2019) Toxoplasmose. https://www.msdmanuals.com/de-de/profi/infektionskrankheiten/extraintestinale-protozoen/toxoplasmose. Zugegriffen: 10. Juni 2021
Pleyer U, Gross U, Schlüter D, Wilking H, Seeber F (2019) Toxoplasmosis in Germany—epidemiology, diagnosis, risk factors, and treatment. Dtsch Arztebl Int 116:435–444
Ramakrishnan C, Maier S, Walker RA, Rehrauer H, Joekel DE, Winiger RR, Basso WU, Grigg ME, Hehl AB, Deplazes P, Smith NC (2019) An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats. Sci Rep 9:1474
Robert Koch-Institut (2018) Toxoplasmose: RKI-Ratgeber. https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Toxoplasmose.html. Zugegriffen: 20. Aug. 2021
Sonaimuthu P, Ching XT, Fong MY, Kalyanasundaram R, Lau YL (2016) Induction of protective immunity against Toxoplasmosis in BALB/c mice vaccinated with Toxoplasma gondii Rhoptry‑1. Front Microbiol 7:808
Speare R, Beveridge I, Johnson PM, Corner LA (1983) Parasites of the agile wallaby, macropus agilis (Marsupialia). Aust Wildl Res 10:89–96
Splendore A (1908) Un nuovo protozoa parassita deconigli incontrato nelle lesioni anatomiche d’une malattia che ricorda in molti punti il Kala-azar dell’uoma. Nota preliminare pel. Rev Soc Sci Sao Paulo 3:109–112
Storch V, Welsch U (2014) Protozoa, Einzellige Tiere III: Apicomplexa (=Sporozoa i.e.s.). In: Storch V, Welsch U (Hrsg) Kükenthal: Zoologisches Praktikum, 27. Aufl. Springer Spektrum, Wiesbaden, S 28–35
auf der Straße U (2019) Die Symptome einer aktiven Toxoplasmose. In: auf der Straße U (Hrsg) Das Toxoplasmose Handbuch: Ein Parasit täuscht die Medizin und macht uns krank – die aktive Toxoplasmose erkennen und behandeln, 2. Aufl. BoD – Books on Demand, Norderstedt, S 46–49
Suzuki Y, Wang X, Jortner BS, Payne L, Ni Y, Michie SA, Xu B, Kudo T, Perkins S (2010) Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells. Am J Pathol 176(4):1607–1613
Teimouri A, Azami SJ, Keshvaraz H, Esmaeili F, Alimi R, Mavi SA, Shojaee S (2018) Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomed 13:1341–1351
Tenter AM, Heckeroth AR, Weiss LM (2000) Toxoplasma gondii: from animals to humans. Int J Parasitol 30:1217–1258
Torun N, Sherif Z, Garweg J, Pleyer U (2008) Diagnostik und Behandlung der okulären Toxoplasmose – Eine Bestandsaufnahme unter deutschsprachigen Ophthalmologen. Ophthalmologe 105(11):1023–1028
Vartak A, Sucheck SJ (2016) Recent advances in subunit vaccine carriers. Vaccines 4:12
Wallon M, Peyron F (2018) Congenital Toxoplasmosis: a plea for a neglected disease. Pathogens 7:25
Wang JL, Li TT, Elsheikha HM, Chen K, Cong W, Yang WB, Bai MJ, Huang SY, Zhu XQ (2018) Live attenuated Pru:Δcdpk2 strain of Toxoplasma gondii protects against acute, chronic, and congenital toxoplasmosis. J Infect Dis 218:768–777
Wang JL, Elsheikha HM, Zhu WN, Chen K, Li TT, Yue DM, Zhang XX, Huang SY, Zhu XQ (2017) Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice. Front Immunol 8:730
Wang L, Tang D, Yang C, Yang J, Fang R (2020) Toxoplasma gondii ADSL knockout provides excellent immune protection against a variety of strains. Vaccines 8:16
Yang WB, Wang JL, Gui Q, Zou Y, Chen K, Liu Q, Liang QL, Zhu XQ, Zhou DH (2019) Immunization with a live-attenuated RH:ΔNPT1 strain of Toxoplasma gondii induces strong protective immunity against toxoplasmosis in mice. Front Microbiol 10:1875
Yang J, Yang C, Qian J, Li F, Zhao J, Fang R (2020) Toxoplasma gondii α‑amylase deletion mutant is a promising vaccine against acute and chronic toxoplasmosis. Microb Biotechnol 13:2057–2069
Yu Z, Zhou T, Luo Y, Dong L, Li C, Liu J, Luo J, Yan R, Xu L, Song X, Li X (2020) Modulation effects of Toxoplasma gondii histone H2A1 on murine macrophages and encapsulation with polymer as a vaccine candidate. Vaccines 8:731
Zylka-Menhorn V (2013) Toxoplasmose-Test: Argumente für ein Screening. Dtsch Arztebl 110(10):A-446/B-399/C-399
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
Y. Borkens gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
M. Wehling, Mannheim
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Borkens, Y. Toxoplasma gondii – gegenwärtige Arzneimittel und zukünftige Impfstoffe gegen eine unterschätzte Protozoonose. Internist 62, 1123–1132 (2021). https://doi.org/10.1007/s00108-021-01155-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-021-01155-1